Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China.
J Dermatol. 2021 Feb;48(2):223-227. doi: 10.1111/1346-8138.15649. Epub 2020 Nov 12.
Diffuse plane xanthomas (DPX) is a rare, chronic, metabolic skin disease which can seriously affect the appearance of the patients and result in psychological problems. Existing treatments are seriously limited. Our objective was to assess the efficacy of and tolerance to simvastatin ointment for the treatment of skin lesions in seven DPX patients. In this study, patients were treated twice daily on the right side of the lesions for 10 months with the 1% or 5% simvastatin ointment. Meanwhile, the left body was untreated as a contralateral controlled side. Efficacy was assessed via the change of rash and was further confirmed by histological study. For all seven participants, both the 1% and 5% simvastatin ointments were effective. The histological change in DPX showed significant decrease of foam cells in skin lesions. The immunohistochemical staining of CD68, macrophage scavenger receptor type 1, oxidized low-density lipoprotein receptor 1 and Oil Red O became obviously reduced after treatment. The test medicines were safe with only some skin-related side-effects. This is the first research reported on simvastatin ointment treatment in DPX. Our results are the first to suggest that simvastatin ointment is effective in improving skin lesions of DPX clinically and histopathologically.
弥漫性黄色瘤（DPX）是一种罕见的、慢性的、代谢性皮肤病，可严重影响患者的外观，并导致心理问题。现有的治疗方法严重受限。我们的目的是评估辛伐他汀软膏治疗 7 例 DPX 患者皮肤病变的疗效和耐受性。在这项研究中，患者在 10 个月内每天两次在病变的右侧使用 1%或 5%的辛伐他汀软膏治疗。同时，左侧身体作为对照侧未经治疗。通过皮疹的变化评估疗效，并通过组织学研究进一步证实。对于所有 7 名参与者，1%和 5%的辛伐他汀软膏均有效。DPX 的组织学变化显示皮肤病变中泡沫细胞明显减少。治疗后 CD68、巨噬细胞清道夫受体 1、氧化型低密度脂蛋白受体 1 和油红 O 的免疫组化染色明显减少。试验药物安全，仅有一些皮肤相关的副作用。这是首次报道辛伐他汀软膏治疗 DPX 的研究。我们的结果首次表明，辛伐他汀软膏在改善 DPX 的皮肤病变方面具有临床和组织病理学疗效。
